Hematology Analyzer Market

Hematology Analyzer Market Overview:

The global hematology analyzer market size was valued at $1,962.40 million in 2020 and is projected to reach $3,941.10 million by 2030 registering a CAGR of 7.30% from 2021 to 2030. Hematology analyzers are computerized, highly specialized machines that count the number of different types of red and white blood cells, blood platelets, hemoglobin, and hematocrit levels in a blood sample. They include programmable automated alarm systems for indicating results outside the reference range. Hematology analyzers are concerned with detection, monitoring of diseases, prognosis and subsequent screening and are extensively used against various blood related diseases such as hemophilia, blood cancer and blood clots. Other diseases include leukemia, anemia, blood transfusion, malignant lymphomas, and others where hematology diagnosis is used.

The COVID-19 pandemic has helped the industry grow significantly, as the demand for hematology analyzer increased owing to increase in focus on the hematology parameters for the assessment of COVID-19 around the world. This supports the hematology analyzer market to gain traction during the forecast period.

Rise in prevalence of blood disorders such as anemia, blood cancers, hemorrhagic conditions, and infections in the blood, is a major factor that drives the growth of the market. In addition, technological advancements in hematology analyzers, and growth in demand for automated hematology analyzer coupled with rising preference toward high sensitivity hematology analyzer further fuel the growth of the hematology analyzer market. However, high cost of hematology analyzers owing to advanced features and automation may hinder the growth of the market. Furthermore, stringent regulatory policies for hematology analyzers are also expected to limit the growth of the market. In contrast, growth opportunities in emerging economics expected to offer lucrative opportunities for players in the hematology analyzer market.

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there is positive effect on the hematology analyzer market owing to increase in focus on the hematology parameters for the assessment of COVID-19 around the world. Several studies are carried out in research institutions, and many of the hospitals started using the hematology analyzers to test and monitor COVID-19 patients without spreading the virus. For the practical and efficient screening of the large populations for the COVID-19 infection, some research studies from China recommended including white blood cells (WBC) and C-reactive protein (CRP) in laboratory examinations for early monitoring of infection. On March 18, 2020, Sight announced that Israel’s government-run Sheba Tel Hashomer Hospital is using its OLO, the first blood count device for point-of-care to conduct CBC tests to monitor and treat its COVID-19 patients to mitigate the risk of contamination.

hematology analyzer market segmentation 

The global hematology analyzer market is segmented on the basis of product & service, type, end user, and region to provide a detailed assessment of the market. By product & service, it is classified into instruments, reagent & consumables, and services. By type, it is segmented into fully-automated hematology analyzer and semi-automated hematology analyzer. Based on end user, it is categorized into hospitals, clinical laboratories, research institutes, and others. Other segment includes blood banks, and biopharma companies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

Based on product & service, the hematology analyzer market is segmented into instruments, reagent & consumables, and services. Reagent & consumables segment dominated the global market in 2020 and is expected to remain dominant throughout the forecast period owing to factors such as increase in adoption of reagent and consumables in clinical laboratories for blood cell counts, coagulation testing, other hematology tests, control, and calibration.

Based on type, it is segmented into fully-automated hematology analyzer and semi-automated hematology analyzer. Fully-automated hematology analyzer segment dominated the global market in 2020 and is anticipated to continue this trend during the forecast period. This is attributed to growing preference for automated hematology instruments, along with increasing technological advancements, and the combination of basic flow-cytometry techniques in automated hematology analyzers.

Based on end user, it is classified into hospitals, clinical laboratories, research institutes, and others. Other segment includes blood banks, and biopharma companies. Clinical laboratories segment held the largest share in 2020 and is expected to remain dominant throughout the forecast period owing to presence of high-quality equipment in clinical laboratories and the accurate results obtained from them. Furthermore, convenience and accurate results in clinical laboratories are the two major reasons driving the growth of the segment during the forecast period.

Snapshot of the Asia-Pacific hematology analyzer market 

Asia-Pacific offers profitable opportunities for key players operating in the hematology analyzer market, thereby registering the fastest growth rate during the forecast period, owing to growing healthcare infrastructure, increasing prevalence of blood diseases, rising disposable incomes, well-established presence of domestic companies, and aging population in the region. In addition, factors such as increase in population and growth in the economies of developing countries such as India and China, are also supporting the growth of the hematology analyzer market in Asia. Technological advancements coupled with supportive investments and funds by the government, especially in developing countries, such as India and China, are also expected to contribute to market growth.

The key market players profiled in the report include Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), Bio-Rad Laboratories, Boule Diagnostics AB, F Hoffmann-La Roche Ltd, Hobira Ltd, Nihon Kohden Corporation, Siemens Healthineers, Stratec SE (Diatron MI Plc.), and Sysmex Corporation.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the global hematology analyzer market along with the current trends and future estimations to explain the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the hematology analyzer market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing hematology analyzer market opportunities.
• Extensive analysis of the key segments of the industry helps to understand the application and products of hematology analyzer used across the globe.
• Key market players and their strategies have been analyzed to understand the competitive outlook of the hematology analyzer market.

Key Market Segments

By Product & Service

• Instruments
• Reagents & Consumables
• Services

By Type

• Fully-Automated Hematology Analyzers
• Semi-automated Hematology Analyzers

By End User

• Hospitals
• Clinical Laboratories
• Research Institutes
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA  

 Hematology Analyzer Market Report Highlights